EMJ Quickfire Q&A: Roberto Mina
Quickfire Q&A delivers in-person insights from congresses, bringing together expert perspectives on the studies and data shaping clinical practice.
In this episode, recorded at the European Hematology Association (EHA) 2026 Congress, we speak to Roberto Mina, Assistant Professor, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA, about the latest developments in multiple myeloma and the growing impact of immunotherapy across the treatment pathway.
Key topics discussed include:
- MonumenTAL-3: Could talquetamab-based combinations redefine treatment in early relapsed multiple myeloma?
- MajesTEC-9: The data positioning teclistamab as a potential new standard of care from second line onwards.
- CEPHEUS: How D-VRd is strengthening the case for frontline quadruplet therapy through deeper, more durable responses.
Disclosure: Mina has received consulting fees from Johnson & Johnson, Pfizer, Sanofi, GSK, BMS, and Regeneron; and acted as Principal Investigator for MajesTEC-9.
Read the latest issue of EMJ Hematology, publishing on 23rd July, for more expert insights and highlights from EHA 2026.
